CEO Dr. Victor Dzau: Directing Duke University Health With a Passion for Medicine, Health Equality
Dr. Dzau is a pioneer in medicine. He was one of the first to introduce DNC decoy molecules to block transcriptions as gene therapy in vivo. Two of his discoveries, E2F decoy and nitric oxide synthase gene therapy, are now under evaluation for clinical trials. Dr. Dzau also serves as the James B. Duke Professor of Medicine and director of molecular and genomic vascular biology at Duke and continues his laboratory studies in cardiovascular translational research.
Dr. Dzau has a passion for in eliminating health disparities among underrepresented populations and the socioeconomically disadvantaged. Since becoming chancellor for health affairs at Duke, he has worked with university leaders to create a campus wide multidisciplinary global health initiative that will draw on Duke resources to improve medical care for the underserved in North Carolina, the United States and internationally.
Dr. Dzau received his medical degree from McGill University Faculty of Medicine in Montreal, Canada and underwent postgraduate training at Harvard Medical School in Boston. Prior to serving Duke, Dr. Dzau was the Hersey Professor of Theory and Practice of Physic (Medicine) at Harvard Medical School. He also served as chairman of the Department of Medicine, physician in chief and director of research at Brigham and Women's Hospital in Boston.
More Articles on CEO Profiles:
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.